Vitamin D

70
VITAMIN D RICKETS DR KAUSIK SUR D.C.H,DNB ASSISTANT PROFESSOR DEPARTMENT OF PEDIATRICS VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES RAMAKRISHNA MISSION SEVA PRATISTHAN KOLKATA,INDIA

Transcript of Vitamin D

Page 1: Vitamin D

VITAMIN DRICKETS

DR KAUSIK SUR D.C.H,DNB

ASSISTANT PROFESSORDEPARTMENT OF PEDIATRICS

VIVEKANANDA INSTITUTE OF MEDICAL SCIENCESRAMAKRISHNA MISSION SEVA PRATISTHAN

KOLKATA,INDIA

Page 2: Vitamin D
Page 3: Vitamin D
Page 4: Vitamin D
Page 5: Vitamin D

SOURCE

• Fish liver oil• Fatty fish• Egg yolk• Fortified foods- formula and milk (400 IU/L)

Page 6: Vitamin D
Page 7: Vitamin D
Page 8: Vitamin D

MECHANISM OF ACTION

Page 9: Vitamin D
Page 10: Vitamin D

INTESTINAL MECHANISM

• 1,25(OH)2D3 increases the efficacy of small intestine to absorb dietary calcium

Vitamin D receptors are most abundant in duodenum, followed by jejunum and ileum

Page 11: Vitamin D

RENAL REABSORPTION

• 1,25(OH)2D3 increases distal tubular reabsorption of calcium

Page 12: Vitamin D

EFFECT ON BONE

• Constant turnover (dynamic equil.) of the ions of bone crystal between those in the bloodstream and those stored in the bone itself- an important feature both in formation and repair

• Vitamin D plays an important role in the regulation of osteoblast and osteoclast activity and in the control of bone matrix protein synthesis

Page 13: Vitamin D

CAUSES OF RICKETS

VITAMIN D DISORDERS• Nutritional Vitamin D

deficiency• Congenital Vitamin D

deficiency• Secondary Vitamin D

deficiency Malabsorption Increased degradation Decreased Liver 25-hydroxylase

• Vitamin D dependent ricket Type 1

• Vitamin D dependent ricket Type 2

• Chronic Renal Failure

CALCIUM DEFICIENCY• Low intake Diet Premature Infant• Malabsorption Primary Disease Dietary inhibitors of calcium absorption

PHOSPHORUS DEFICIENCYInadequate intake Premature infants Aluminium containing antacids

Page 14: Vitamin D

RENAL LOSSES• X- linked hypophosphatemic

ricket• AD hypophosphatemic

ricket• Hereditary

hypophosphatemic ricket with hypercalcuria

• Overproduction of phosphatonin

Tumour induced rickets Mccune albright syndrome Epidermal nevus syndrome Neurofibromatosis

• Fanconi syndrome• Dent Disease

DISTAL RENAL TUB. ACIDOSIS

Page 15: Vitamin D

CLINICAL FEATURES OF RICKET

GENERAL• FTT• Listlessness• Protruding Abdomen,UMBILICAL HERNIA

hypotonia of abdominal wall muscles

• Muscle Weakness(specially proximal)• Fractures

Page 16: Vitamin D

HEAD• CRANIOTABES softening of cranial bones

• Frontal Bossing

• Delayed Fontanelle Closure

• Delayed Dentition, early numerous caries, enamel hypoplasia- mostly deciduous teeth are concerned

• Craniosynostosis

Page 17: Vitamin D

CHEST

• RACHITIC ROSARY

Widening of costochondral junction

• Harrison Groove pulling of softened ribs by the diaphragm during inspiration

Muscle traction on the softened rib cage

• Pectus carinatum• Thoracic asymmetry• Widening of thoracic bone• Respiratory Infections • Atelectasis impairment of air movement

Page 18: Vitamin D

BACKDeformities of spine and pelvis are very unusual today-

described in severe long atanding rickets

• Scoliosis

• Kyphosis

• Lordosis

Page 19: Vitamin D

EXTREMITIES• Enlargement of wrists and ankles Growth plate widening

• Valgus or varus deformities

Page 20: Vitamin D

•WINDSWEPT DEFORMITYcombination of varus deformity of 1 leg with valgus deformity of other leg

•Anterior bowing of tibia and femur

•Coxa Vara

•Leg pain

Page 21: Vitamin D

HYPOCALCEMIC SYMPTOMS• Tetany

• Seizures

• Stridor due to laryngeal spasm

Page 22: Vitamin D

VARIATION IN CLINICAL PRESENTATION BASED ON ETIOLOGY

• XLHypophosphatemic rickets- Changes in lower extremity is dominant feature

• symptoms secendary to hypocalcemia occour only in Ricket associated with decreased serum calcium

Page 23: Vitamin D

INVESTIGATIONS

RADIOLOGY• Changes are most easily visualized on PA view of wrist-

although characteristic racitic changes are seen at other growth plates

• Alterations of the epiphyseal regions of the long bones- most characteristic

• Accumulation of uncalcified cartilage

Widening of the radiolucent space between end of bone shafts (metaphyseal lines) and epiphysis

Page 24: Vitamin D

• Decreased calcification

thickening of growth plate

Page 25: Vitamin D
Page 26: Vitamin D

• Edge of metaphysis loses its sharp border

FRAYING• Edge of metaphysis changes from convex or flat

surface to a more concave surface CUPPING (most easily seen at distal ends of radius, ulna and

fibula)

• Widening of Metaphyseal end of bone SPLAYING• Metaphyseal lines spread laterally forming

CORTICAL SPURS• Widening of distal ends of metaphysis

thickened wrist and ankles, rachitic rosary

Page 27: Vitamin D

• Changes of diaphysis – appear a few weeks later

Coarse trabeculation generalized rarefactionCortical thinningSubperiosteal erosion

Page 28: Vitamin D

• Insufficient mineralization centres of ossification are pale, irregular

• Shafts of long bones- diminished density with thinning of cortices

• Severe rickets in young infant- shadowy shaft, almost complete disappearance of cortices

• Older children with long standing rickets- apparently paradoxical thickening of cortices- from superimposition of layers of partially mineralized osteoid

Page 29: Vitamin D

Decreased density of RibsScapula Pelvisskull

Page 30: Vitamin D

VITAMIN D DEFICIENCYETIOLOGY• Most commonly occur in infancy due to poor intake and

inadequate cutaneous synthesis• Formula fed infants- receive adequate vit D even without

cutaneous synthesis• Breast fed infants rely on cutaneous synthesis or vitamin d

supplements Cutaneous synthesis is limited due to Ineffectiveness of winter sun Avoidance of sunlight Decreased cutaneous synthesis due to increased skin

pigmentation

Page 31: Vitamin D

LABORATORY FINDINGS• Hypocalcemia – variable finding due to action of

↑PTH • Hypophosphatemia- due to PTH induced renal

loss of phosphate and decreased intestinal absorption

• 1,25D level-N,↑,↓- secondary to up regulation of renal 1 α hydroxylase due to hypophosphatemia and hyperparathyroidism

• Some patients have Metabolic acidosis secondary to PTH induced renal bicarbonate wasting

• Generalized aminoaciduria

Page 32: Vitamin D

MANAGEMENT OF VITAMIN D DEFICIENCY

• Should receive Vitamin D and adequate nutritional intake of calcium and phosphorus

• STROSS THERAPY- 3-6 Lakh IU of Vitamin D oral/IM as 2-4 doses over 1 day

0R Daily High dose Vitamin D 2000-5000 IU/day

over 4-6 weeks

Daily Vitamin D intake of 400 IU/day

Page 33: Vitamin D

• Symptomatic Hypocalcemia- I V calcium

followed by oral calcium supplements- can be tapered over 2-6 weeks in children who receive adequate dietary calcium

Page 34: Vitamin D

PREVENTION OF VITAMIN D DEFICIENCY

Universal administration of a daily multivitamin containing 200-400 IU of Vitamin D to children who are breast fed

For older children, the diet should be reviewed to ensure that there is a source of Vitamin D

Page 35: Vitamin D

THERAPEUTIC POTENTIALS OF 1,25(OH)2D3

ANALOGUES• 25(OH)D, 1 α HYDROXYLASE and VDR are present in Keratinocytes Monocytes Bone Placenta

• Capable of regulating cell differentiation and proliferation of both normal and malignant cells

new therapeutic modality for immune modulation incl. treatment of autoimmune disease or prevention of graft

rejection Inhibition of cell proliferation( e.g.) psoriasis Induction of cell differentiation(cancer)

Page 36: Vitamin D

BONE DISORDERS• Vitamin D analogue 2b(3hydroxy proxy)- 1,252D

(ED71)- high calcemic activity and strong binding to DBP BEING TESTED IN CLINICAL OSTEOPORESIS TRIALS

• Several other analogues like 1α(OH) D2 and 19-nor 1,25(OH)2-D are being evaluated

• 1α(OH) D3 and 1,25(OH)2-D are widely used for prevention and cure of renal osteodystrophy

Page 37: Vitamin D

CANCER• Several 1,25(OH)2-D analogues have been developed

with potent anti proliferative and pro differentiating effects on cancer cells in vitro and reduced effects on bone metabolism

• These are potent inhibitors of cancer cell growth, angiogenesis, metastasis with reduced calcemic activity

Promising for their potential use in cancer treatment

Page 38: Vitamin D

SKIN• Epidermal keratinocytes are chr. By Capacity to produce vitamin D3 Presence of VDR Expression of 25(OH)D 1α Hydroxylase and CYP27 and 25-hydroxylase activity

Irradiated keratinocytes can fulfill their own Vitamin D requirements and may serve as a defence mechanism against the harmful effects of vitamin D

• Increased secretion of extracellular matrix molecules such as fibronectin and osteopontin in vitamin D treated keratinocytes

Beneficial for wound healing• Hyper proliferative epidermis is psoriasis responds to vitamin D

derivatives with growth arrest

Page 39: Vitamin D

HAIRTopical vitamin D compounds alleviate or even

induce resistance against chemotherapy dependant alopecia

Page 40: Vitamin D

IMMUNITY• Vitamin D receptors are present in cells of the

immune system like antigen presenting cells(macrophages and dendritic cells) Activated T-lymphocytes

• Vitamin D acts as an immunomodulator

Page 41: Vitamin D

CONGENITAL VITAMIN D DEFICIENCY

• Occur when there is severe maternal vitamin D deficiency during pregnancy

Risk factors- Poor dietary intake of Vitamin D Lack of adequate sun exposure Closely spaced pregnancies

Page 42: Vitamin D

Clinical Features• Symptomatic hypocalcemia• IUGR• Decreased bone ossification + classic rachitic

changes

Page 43: Vitamin D

Treatment• Vitamin D supplementation• Adequate intake of calcium and phosphorus• Use of prenatal vitamin D

Page 44: Vitamin D

SECENDARY VITAMIN D DEFICIENNCY

ETIOLOGY• Liver and GI diseases incl.1. Cholestatic Liver Disease2. defect in bile acid metabolism3. cystic fibrosis and other causes of pancreatic dysfunction

• Celiac disease• Chrons disease • Intestinal Lymphangiectasia• Intestinal resection• Medications- anticonvulsants (phenobarbitone,

phenytoin, isoniazid, rifampicin)

Page 45: Vitamin D

TREATMENTVitamin D deficiency due to malabsorption- high

dose of Vitamin D 25-D 25-50 µg/day or 5-7 µg/kg/day superior to D3 dose adjusted based on serum 25D or

1,25-D better absorbed in presence of fat malabsorption or

PARENTERAL VIT. D

Page 46: Vitamin D

VITAMIN D DEPENDENT RICKET TYPE 1

• AR• Mutation in the gene encoding renal 1α

hydroxylase• Present during first 2 yr of life• Can have any of the classical features of

rickets incl. symptomatic hypocalcaemia• Normal level 25-D, low 1,25-D

Page 47: Vitamin D

TREATMENT• Long term treatment with 1,25-D(calcitriol) initial dose 0.25-2 µg/day lower doses used once ricket has healed• Adequate intake of calciumDose of calcitriol is adjusted to maintain a low normal serum ca,

normal serum P, high normal serun PTHLow normal ca and high normal PTH avoids excessive dose of

calcitriol(causes hypercalcuria, nephrocalcinosis)Monitoring-periodic addessment of urinary calcium excretion Target <4mg/kg/day

Page 48: Vitamin D

VITAMIN D DEPENDENT RICKET TYPE 2

• AR• Mutation in the gene encoding the vitamin D

receptor prevention of normal physiologic response to 1,25 D

• Level of 1,25-D extremely elevated• 50-70% have Alopecia (tend to be associated with

more severe form of the disease)

• Epidermal cysts- less common

Page 49: Vitamin D

TREATMENTSome patients specially those without alopecia

responds to extremely high dose of vitamin D2, 25-D or 1,25-D ( due to partially functional vitamin d receptor)

All pts should be given a 3-6 months trial of high dose Vitamin D and oral calcium

initial dose of 1,25-D 2µg/day(some require 50-60 µg/day)

Calcium 1000-3000mg/dayPts not responding to high dose Vitamin D – long

term I V calcium, with possible transition to very high dose oral calcium supplement

Page 50: Vitamin D

CHRONIC RENAL FAILURE

• Decreased activity of 1 α hydroxylase in the kidney

• Decresaed renal excretion of phosphate hyperphosphatemia• Direct effect of CRF on growth hormone axis FTT and growth retardation may be

accentuated

Page 51: Vitamin D

TREATMENTCalcitriol (act without 1 α hydroxylase )

Normalization of serum phosphorus level byo Dietary phosphorus restrictiono Oral phosphate binders

Correction of chronic metabolic alkalosis by alkali

Page 52: Vitamin D

CALCIUM DEFICIENCY

• Early weaning( breast milk and formula are excellent source of calcium)

• Diet with low calcium content( <200 mg/day)• Diet with high phytate, oxalate, phosphate( due to reliance

on green leafy vegetables decreased absorption of dietary calcium

• Children with unconventional diet (children with milk allergy)

• Transition from formula or breast milk to juice, soda, calcium poor soy milk without alternative source of dietary calcium

• I V nutrition without adequate calcium• Calcium malabsorption- celiac disease, inteatinal

abetalipoproteinemia, small bowel resection

Page 53: Vitamin D
Page 54: Vitamin D

CLINICAL MANIFESTATION• Classical s/s of rickets• Presentation may occur during

infancy/childhood although some cases are diagnosed at teen age

• Occur later than nutritional vitamin D deficiency

Page 55: Vitamin D

DIAGNOSIS• ↑alkaline phosphatase, PTH, 1,25-D• calcium ↓ or normal• ↓ urinary calcium• ↓ serum P level( renal wasting from

secendary hyperparathyroidism)

Page 56: Vitamin D

TREATMENT• Adequate calcium- as dietary supplement 350-1000 mg/day of elemental calcium• Vitamin D supplementation- if there is

concurrent vit. D def.

Page 57: Vitamin D

PREVENTION• Discouraging early cessation of breast feeding• Increasing dietary sources of calcium

Page 58: Vitamin D

PHOSPHORUS DEFICIENCY

INADEQUATE INTAKE• Decreased P absorption- celiac disease Cystic fibrosis Cholestatic liver disease

• Isolated P malabsorption- long term use of P containing antacids

Page 59: Vitamin D

X LINKED HYPOPHOSPHATEMIC RICKETS

• Most common genetic disorder causing ricket due to hypophosphatemia

• Defective gene is on x- chromosome, but female carriers are affected(x linked dominant)

Page 60: Vitamin D

PATHOPHYSIOLOGY• Defective gene is called PHEX because it is a PHosphate regulating

gene with homology to Endopeptidases on the x-chromosome

Product of this gene appears to have either a direct or an indirect role in inactivating a phosphatonin – FGF23 may be the target phosphatonin

Absence of PHEX decreased degradation of phosphatonin

1.increased phosphate excretion 2. decreased production of 1,23-D

Page 61: Vitamin D

CLINICAL FEATURESAbnormalities of lower extremities and poor

growth are dominant featureDelayed dentitionTooth abscessHypophosphatemia

Page 62: Vitamin D
Page 63: Vitamin D

LABORATORY FINDINGS• High renal excretion of phosphate• Hypophosphatemia• Increased alkaline phosphatase• Normal PTH and serum calcium

Page 64: Vitamin D

TREATMENTA combination of Oral Phosphorus and 1,25-DPhosphorus- 1-3 gm of elemental P divided into

4-5 dosesCalcitrol - 30-70 ng/kg/day in 2 div. doses

Page 65: Vitamin D

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS

• Less common than XLH• Variable age of onset• Mutation in the gene encoding FGF-23 Degradation of FGF-23 by proteases is prevented

Increased phosphatonin level( phosphatonin decreases renal tubular reabsorption of phosphate)

HypophosphatemiaInhibition of 1 αhydroxylase in kidney

decreased ,25D synthesis

Page 66: Vitamin D

LABORATORY FINDINGSHypophosphatemia↑alkaline phosphatase↓ or inappropriately normal 1,25D level

TREATMENTSimilar to XLH

Page 67: Vitamin D

HEREDITARY HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCURIA

• Primary problem- renal phosphate leak

hypophosphatemia

stimulation of production of 1,25D

high level of 1,25 D increases intestinal absorption of calcium

PTH suppression

hypercalcuria

Page 68: Vitamin D

CLINICAL MANIFESTATIONSDominant symptoms are • rachitic leg abnormalities• Muscle weakness• Bone pain

Patients may have short stature with a disproportionate decrease in lenth of lower extr.

Page 69: Vitamin D

LABORATORY FINDINGSHypophosphatemiaRenal phosphate wasting↑serum alkaline phosphatase↑1,25D level

Page 70: Vitamin D

TREATMENTOral phosphate replacement1-2.5gm of elemental phosphorus in 5 divided

oral doses